JP2024526773A5 - - Google Patents

Info

Publication number
JP2024526773A5
JP2024526773A5 JP2024502056A JP2024502056A JP2024526773A5 JP 2024526773 A5 JP2024526773 A5 JP 2024526773A5 JP 2024502056 A JP2024502056 A JP 2024502056A JP 2024502056 A JP2024502056 A JP 2024502056A JP 2024526773 A5 JP2024526773 A5 JP 2024526773A5
Authority
JP
Japan
Prior art keywords
approximately
cancer
pharmaceutical composition
composition according
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526773A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073462 external-priority patent/WO2023288173A1/en
Publication of JP2024526773A publication Critical patent/JP2024526773A/ja
Publication of JP2024526773A5 publication Critical patent/JP2024526773A5/ja
Pending legal-status Critical Current

Links

JP2024502056A 2021-07-16 2022-07-06 B7‐h3抗体の医薬組成物及びその使用 Pending JP2024526773A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
US63/222,750 2021-07-16
PCT/US2022/073462 WO2023288173A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Publications (2)

Publication Number Publication Date
JP2024526773A JP2024526773A (ja) 2024-07-19
JP2024526773A5 true JP2024526773A5 (cg-RX-API-DMAC10.html) 2025-07-10

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502056A Pending JP2024526773A (ja) 2021-07-16 2022-07-06 B7‐h3抗体の医薬組成物及びその使用

Country Status (11)

Country Link
US (1) US20240336687A1 (cg-RX-API-DMAC10.html)
EP (1) EP4370155A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024526773A (cg-RX-API-DMAC10.html)
KR (1) KR20240038005A (cg-RX-API-DMAC10.html)
CN (1) CN117715657A (cg-RX-API-DMAC10.html)
AU (1) AU2022310668A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224118A1 (cg-RX-API-DMAC10.html)
IL (1) IL310187A (cg-RX-API-DMAC10.html)
MX (1) MX2024000690A (cg-RX-API-DMAC10.html)
TW (1) TW202310874A (cg-RX-API-DMAC10.html)
WO (1) WO2023288173A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
EP3714901A4 (en) * 2017-12-22 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20230041197A1 (en) * 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Il-5に対する抗体を含有する医薬組成物及びその使用
KR20220119694A (ko) * 2019-12-23 2022-08-30 마크로제닉스, 인크. 암 치료를 위한 요법
CN115103691B (zh) * 2020-03-25 2025-01-24 苏州盛迪亚生物医药有限公司 一种含抗体药物偶联物的药物组合物及其用途

Similar Documents

Publication Publication Date Title
ES2981830T3 (es) Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
KR102446673B1 (ko) 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
JP2022533578A5 (cg-RX-API-DMAC10.html)
JP2014132009A5 (cg-RX-API-DMAC10.html)
CN115624550B (zh) 一种用于治疗胃癌的喹啉衍生物
JP2012500180A5 (cg-RX-API-DMAC10.html)
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN108778332B (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
WO2019057141A1 (zh) 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
JP7296070B2 (ja) がん免疫療法アジュバント
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
JP2022531980A5 (cg-RX-API-DMAC10.html)
JP6063472B2 (ja) 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質1(TBL1)活性に関連する疾患および障害の処置のための方法
TW200810758A (en) Potentiator of radiation therapy
JP2022519923A5 (cg-RX-API-DMAC10.html)
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
Hotte et al. Final results of a phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers
US20240277722A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
CN110464845A (zh) 一种用于乳腺癌免疫治疗的联合用药物组合及其应用
AU2024362257A1 (en) Methods and compositions for treating tumors using antibody camptothecin drug conjugates
JP2024525566A5 (cg-RX-API-DMAC10.html)
WO2024028846A1 (en) Combination therapy for treating cancers